

Pamela L Wolters

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2069230/publications.pdf>

Version: 2024-02-01

52
papers

4,265
citations

201674

27
h-index

175258

52
g-index

53
all docs

53
docs citations

53
times ranked

5801
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of the coronavirus pandemic on mental health and health care in adults with neurofibromatosis: Patient perspectives from an online survey. <i>American Journal of Medical Genetics, Part A</i> , 2022, 188, 71-82.	1.2	8
2	Adolescents and young adults with neurofibromatosis type 1: A descriptive study of adaptive functioning. <i>American Journal of Medical Genetics, Part A</i> , 2022, 188, 488-497.	1.2	3
3	Neurotoxicity following CD19/CD28 ⁺ CAR T-cells in children and young adults with B-cell malignancies. <i>Neuro-Oncology</i> , 2022, 24, 1584-1597.	1.2	12
4	The Needs of Adolescents and Young Adults with Chronic Illness: Results of a Quality Improvement Survey. <i>Children</i> , 2022, 9, 500.	1.5	13
5	Verbal learning and memory in youth with neurofibromatosis type 1 and plexiform neurofibromas: Relationships with disease severity. <i>European Journal of Paediatric Neurology</i> , 2022, 38, 7-12.	1.6	1
6	Selumetinib in children with neurofibromatosis type 1 and asymptomatic inoperable plexiform neurofibroma at risk for developing tumor-related morbidity. <i>Neuro-Oncology</i> , 2022, 24, 1978-1988.	1.2	14
7	Management of neurofibromatosis type 1-associated plexiform neurofibromas. <i>Neuro-Oncology</i> , 2022, 24, 1827-1844.	1.2	29
8	MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus. <i>Neuro-Oncology</i> , 2022, 24, 1845-1856.	1.2	30
9	Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial. <i>Nature Medicine</i> , 2021, 27, 165-173.	30.7	46
10	NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas. <i>Journal of Clinical Oncology</i> , 2021, 39, 797-806.	1.6	54
11	Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL. <i>Journal of Clinical Oncology</i> , 2021, 39, 1650-1659.	1.6	173
12	Recommendations for Social Skills End Points for Clinical Trials in Neurofibromatosis Type 1. <i>Neurology</i> , 2021, 97, S73-S80.	1.1	3
13	Current Recommendations for Patient-Reported Outcome Measures Assessing Domains of Quality of Life in Neurofibromatosis Clinical Trials. <i>Neurology</i> , 2021, 97, S50-S63.	1.1	11
14	Perspective of Adults With Neurofibromatosis 1 and Cutaneous Neurofibromas. <i>Neurology</i> , 2021, 97, S15-S24.	1.1	5
15	Enhancing Neurofibromatosis Clinical Trial Outcome Measures Through Patient Engagement. <i>Neurology</i> , 2021, 97, S4-S14.	1.1	7
16	Beyond the storm – subacute toxicities and late effects in children receiving CAR T cells. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 363-378.	27.6	37
17	Acceptance and commitment therapy for adolescents and adults with neurofibromatosis type 1, plexiform neurofibromas, and chronic pain: Results of a randomized controlled trial. <i>Journal of Contextual Behavioral Science</i> , 2021, 22, 93-101.	2.6	7
18	Neurocognitive functioning in symptomatic adults with sickle cell disease: A description and comparison with unaffected siblings. <i>Neuropsychological Rehabilitation</i> , 2020, 30, 1666-1681.	1.6	11

#	ARTICLE	IF	CITATIONS
19	Advancing <scp>RAS/RASopathy</scp> therapies: An NCI-sponsored intramural and extramural collaboration for the study of <scp>RASopathies</scp>. American Journal of Medical Genetics, Part A, 2020, 182, 866-876.	1.2	40
20	Sleep disturbance in adults with sickle cell disease: relationships with executive and psychological functioning. Annals of Hematology, 2020, 99, 2057-2064.	1.8	6
21	Selumetinib in Children with Inoperable Plexiform Neurofibromas. New England Journal of Medicine, 2020, 382, 1430-1442.	27.0	360
22	Treatment of HIV-associated primary CNS lymphoma with antiretroviral therapy, rituximab, and high-dose methotrexate. Blood, 2020, 136, 2229-2232.	1.4	26
23	Targeting Refractory Sarcomas and Malignant Peripheral Nerve Sheath Tumors in a Phase I/II Study of Sirolimus in Combination with Ganetespib (SARC023). Sarcoma, 2020, 2020, 1-8.	1.3	33
24	Predictors of cognitive development in children with neurofibromatosis type 1 and plexiform neurofibromas. Developmental Medicine and Child Neurology, 2020, 62, 977-984.	2.1	14
25	CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial. Journal of Clinical Oncology, 2020, 38, 1938-1950.	1.6	273
26	Phase II trial of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886 Hydrogen Sulfate) in adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN).. Journal of Clinical Oncology, 2020, 38, 3612-3612.	1.6	12
27	Pharmacodynamic Study of Miransertib in Individuals with Proteus Syndrome. American Journal of Human Genetics, 2019, 104, 484-491.	6.2	56
28	Safety and efficacy of low-dose sirolimus in the PIK3CA-related overgrowth spectrum. Genetics in Medicine, 2019, 21, 1189-1198.	2.4	115
29	An Internet support group for parents of children with neurofibromatosis type 1: a qualitative analysis. Journal of Community Genetics, 2018, 9, 327-334.	1.2	6
30	The Relationship Between Heart Rate Variability, Psychological Flexibility, and Pain in Neurofibromatosis Type 1. Pain Practice, 2018, 18, 969-978.	1.9	23
31	Systematic Evaluation of Neurotoxicity in Children and Young Adults Undergoing CD22 Chimeric Antigen Receptor T-Cell Therapy. Journal of Immunotherapy, 2018, 41, 350-358.	2.4	60
32	Effects of Interrupting Sedentary Behavior With Short Bouts of Moderate Physical Activity on Glucose Tolerance in Children With Overweight and Obesity: A Randomized Crossover Trial. Diabetes Care, 2018, 41, 2220-2228.	8.6	33
33	QOL-55. HOME PHYSICAL ACTIVITY INTERVENTION TO IMPROVE COGNITIVE LATE EFFECTS IN CHILDREN TREATED WITH RADIATION FOR BRAIN TUMORS: DESCRIPTIVE FEASIBILITY DATA FROM A PILOT RANDOMIZED CONTROLLED TRIAL (RCT). Neuro-Oncology, 2018, 20, i168-i168.	1.2	0
34	CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nature Medicine, 2018, 24, 20-28.	30.7	1,030
35	Neurofibromatosis type 1. Nature Reviews Disease Primers, 2017, 3, 17004.	30.5	498
36	Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas. New England Journal of Medicine, 2016, 375, 2550-2560.	27.0	486

#	ARTICLE	IF	CITATIONS
37	Patient-reported outcomes of pain and physical functioning in neurofibromatosis clinical trials. <i>Neurology</i> , 2016, 87, S4-S12.	1.1	36
38	Neurocognitive outcomes in neurofibromatosis clinical trials. <i>Neurology</i> , 2016, 87, S21-30.	1.1	16
39	Acceptance and commitment therapy in youth with neurofibromatosis type 1 (NF1) and chronic pain and their parents: A pilot study of feasibility and preliminary efficacy. <i>American Journal of Medical Genetics, Part A</i> , 2016, 170, 1462-1470.	1.2	41
40	Pain interference in youth with neurofibromatosis type 1 and plexiform neurofibromas and relation to disease severity, social-emotional functioning, and quality of life. <i>American Journal of Medical Genetics, Part A</i> , 2015, 167, 2103-2113.	1.2	72
41	Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a Neurofibromatosis Clinical Trials Consortium phase II study. <i>Neuro-Oncology</i> , 2015, 17, 596-603.	1.2	118
42	Effects of Interrupting Children's Sedentary Behaviors With Activity on Metabolic Function: A Randomized Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 3735-3743.	3.6	61
43	Development and Validation of the English Pain Interference Index and Pain Interference Index-Parent Report. <i>Pain Medicine</i> , 2015, 16, 367-373.	1.9	36
44	Sirolimus for non-progressive NF1-associated plexiform neurofibromas: An NF clinical trials consortium phase II study. <i>Pediatric Blood and Cancer</i> , 2014, 61, 982-986.	1.5	73
45	Patient-reported outcomes in neurofibromatosis and schwannomatosis clinical trials. <i>Neurology</i> , 2013, 81, S6-14.	1.1	39
46	Social-emotional Functioning of Children and Adolescents With Neurofibromatosis Type 1 and Plexiform Neurofibromas: Relationships With Cognitive, Disease, and Environmental Variables. <i>Journal of Pediatric Psychology</i> , 2012, 37, 713-724.	2.1	62
47	Experiences of families with a child, adolescent, or young adult with neurofibromatosis type 1 and plexiform neurofibroma evaluated for clinical trials participation at the National Cancer Institute. <i>Contemporary Clinical Trials</i> , 2011, 32, 10-15.	1.8	12
48	Neurodevelopment of Children Under 3 Years of Age With Smith-Magenis Syndrome. <i>Pediatric Neurology</i> , 2009, 41, 250-258.	2.1	39
49	Adaptive and Maladaptive Behavior in Children with Smith-Magenis Syndrome. <i>Journal of Autism and Developmental Disorders</i> , 2006, 36, 541-552.	2.7	55
50	Abnormally increased semantic priming in children with symptomatic HIV-1 disease: Evidence for impaired development of semantics?. <i>Journal of the International Neuropsychological Society</i> , 2001, 7, 491-501.	1.8	10
51	Neurobehavioral Manifestations of Symptomatic HIV-1 Disease in Children: Can Nutritional Factors Play a Role?. <i>Journal of Nutrition</i> , 1996, 126, 2651S-2662S.	2.9	9
52	White matter changes on ct brain scan are associated with neurobehavioral dysfunction in children with symptomatic HIV disease. <i>Child Neuropsychology</i> , 1995, 1, 93-105.	1.3	21